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ABSTRACT
Receptor tyrosine kinases-based autocrine loops largely contribute to activate 
the MAPK and PI3K/AKT pathways in melanoma. However, the molecular mechanisms 
involved in generating these autocrine loops are still largely unknown. In the present 
study, we examine the role of the transcription factor RUNX2 in the regulation of receptor 
tyrosine kinase (RTK) expression in melanoma. We have demonstrated that RUNX2-
deficient melanoma cells display a significant decrease in three receptor tyrosine kinases, 
EGFR, IGF-1R and PDGFRβ. In addition, we found co-expression of RUNX2 and another 
RTK, AXL, in both melanoma cells and melanoma patient samples. We observed a decrease 
in phosphoAKT2 (S474) and phosphoAKT (T308) levels when RUNX2 knock down resulted 
in significant RTK down regulation. Finally, we showed a dramatic up regulation of RUNX2 
expression with concomitant up-regulation of EGFR, IGF-1R and AXL in melanoma cells 
resistant to the BRAF V600E inhibitor PLX4720. Taken together, our results strongly 
suggest that RUNX2 might be a key player in RTK-based autocrine loops and a mediator 
of resistance to BRAF V600E inhibitors involving RTK up regulation in melanoma.
INTRODUCTION
The RUNX (Runt-related transcription factor) family 
is comprised of three closely related transcription factors, 
RUNX1, RUNX2 and RUNX3. These genes are defined by 
a highly conserved 128 amino acid DNA binding/protein-
protein interaction domain called the Runt-homology 
domain [1]. RUNX2 is a major determinant of osteoblast 
differentiation and regulates chondrocyte proliferation, 
differentiation and hypertrophy during endochondral 
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bone formation [2–5]. In addition, RUNX2 regulates 
the expression of genes closely associated with tumor 
progression, invasion and metastasis [1, 6–9] and has pro-
angiogenic effects [10–13]. We were the first to demonstrate 
that RUNX2 was overexpressed in human melanoma cells 
as compared with normal human melanocytes and that 
RUNX2 deficiency inhibited cell growth, migration and 
invasion of human melanoma cells. In addition, we showed 
that decreased RUNX2 expression was associated with a 
reduction in the expression of FAK [14], implicated in cell 
migration [9, 15] and melanoma metastasis [16–18].
Up-regulation of the expression of EGF-R, 
PDGFRβ, AXL and IGF-1R in melanoma cells that have 
developed resistance to BRAF V600E targeted therapy 
[19–25] results in reactivation of the MAPK and the 
PI3K/AKT pathways. These pathways are crucial not 
only for tumor cell survival and proliferation, but also 
for continued tumor cell migration and invasion [26–31]. 
However, the mechanisms contributing to high levels 
of these RTKs in melanomas have not been elucidated 
either in the context of progressing tumors or in acquired 
resistance to BRAF V600E inhibitors.
An early analysis of the expression of growth factors 
and their receptors in melanomas showed that EGF was 
overexpressed as compared to melanocytes while EGFR 
was expressed in both melanomas and melanocytes. This 
suggests a role for EGF-EGFR-based autocrine signaling 
in melanoma cells [32]. In favor of this role, treatment 
with cetuximab, a monoclonal antibody targeting the 
extracellular domain of EGFR, reduced the invasive ability 
of melanoma cells. Furthermore, in 114 patients with 
primary cutaneous melanomas, EGFR expression was found 
to be associated with metastatic spread to sentinel lymph 
nodes and the presence of EGFR polysomy was correlated 
with thicker primary tumors [33]. FGF-FGFR -based 
autocrine signaling was also suggested by overexpression of 
FGF2, FGF5 and FGF8 and different isoforms of the FGF 
receptors (FGFR1-4) in melanoma cells. In addition, it has 
been shown that stimulation of FGF receptors enhances the 
motility of melanoma cells [32, 34].
IGF1R activation was reported in a panel of 
25 melanoma cell lines derived from primary and 
metastatic lesions [35] and a comprehensive analysis 
of RTK activation in human melanoma samples and 
cell lines identified autocrine signaling through IGF-1R 
[36]. Disruption of the direct interaction between Focal 
Adhesion Kinase (FAK) and IGF-1R by the small molecule 
compound INT2-31 inhibited melanoma xenograft growth 
in association with reduced levels of pAKT (S473) [37]. A 
study on uveal melanoma supports the role of exogenous 
and endogenous IGF-1 and their interaction with IFG-1R in 
the development of metastases in the liver, which is a major 
site for IGF-1 production and the predominant metastatic 
site in 70-90% of uveal melanoma [38]. The contribution 
of IGF-1 to melanoma cell migration was shown to require 
the activation of PI3K by IGF-1R [39].
AXL is activated in melanomas [35] and engaged 
in an autocrine loop due to endogenous production 
of its ligand Gas6 [40]. In addition, AXL promotes the 
pro-migratory and pro-invasive behavior of melanoma cells 
[35, 40] and resistance to the BRAF V600E inhibitor 
PLX4720 [20]. These findings are reinforced in a more 
recent study, which demonstrated an increased resistance 
to BRAF and ERK inhibition in melanoma cells expressing 
low levels of MITF (Microphthalmia-associated 
transcription factor) and high levels of AXL. This study 
also showed a reverse correlation between MITF and 
receptor tyrosine kinases, including AXL [21]. This study 
confirmed the negative correlation between MITF and 
AXL in melanoma cells [40, 41]. Since loss of MITF is also 
accompanied by increased invasiveness [21, 42], it supports 
previous findings that a high level of AXL expression is 
associated with a pro-invasive phenotype in melanoma.
The present study was designed to investigate the 
relationship between RUNX2 and the expression of receptor 
tyrosine kinases (RTKs) in melanoma. We demonstrated the 
co-expression of RUNX2 with IGF-1R, EGF-R, PDGFRβ 
and AXL using ShRNA RUNX2-expressing melanoma cells 
and showed co-expression of RUNX2 with AXL in human 
melanoma samples. Most importantly, we demonstrate for 
the first time that melanoma cells resistant to the BRAF 
V600E inhibitor PLX4720 had a significant increase in 
RUNX2 expression associated with an increase in RTKs 
expression and activation. In addition, melanoma cells with 
reduced expression of RUNX2 had an increased sensitivity 
to PLX4720. We suggest that RUNX2 may be a driver of 
increased receptor-tyrosine kinase (RTK)-based autocrine 
signaling in melanoma and a key player in resistance to 
targeted therapies involving up regulation of different RTKs.
RESULTS
ShRNA-mediated depletion of RUNX2 reduces 
RTKs expression
We previously demonstrated that knock down of 
RUNX2 using RUNX2 shRNA lentiviral expression 
vectors decreased melanoma cell migration and invasion. 
These findings suggest a role for RUNX2 in the migration 
and invasive ability of melanoma cells [14]. In order to 
define potential mediators of the RUNX2-mediated effects 
on migration and invasion, we generated 250 μg of proteins 
from stable 1205LU melanoma cell lines expressing two 
types of RUNX2 ShRNA; ShRUNX2-2 (targeting RUNX2 
3′UTR) and ShRUNX2-3 (targeting the RUNX2 coding 
sequence) as previously described [14]. We then performed 
a quantitative analysis of proteins up- or down-regulated 
in the RUNX2 knocked down 1205LU cells relative to 
non-silencing ShRNA-expressing 1205LU cells using 
mass spectrometry. As shown in Table 1, reduced levels of 
the receptor tyrosine kinases IGF-1R, FGFR1, PDGFRβ, 
and EGFR were detected in the RUNX2 knocked down 
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Figure 1: RUNX2 knock down results in reduced expression of RTKs. A. Lysates from melanoma cell lines were analyzed for the 
expression of IGF-1R, FGFR1, PDGFRβ, EGFR and AXL. B. RUNX2 and RTKs levels in non-silencing ShRNA (NS), ShRUNX2-2 (Sh2) 
and ShRUNX2-3 (Sh3) stable melanoma cell lines. C. Levels of pAKT(T308), pAKT1(S473), pAKT2(S474), AKT, pERK1/2, ERK1/2 and 
Actin in non-silencing ShRNA (NS), ShRUNX2-2 (Sh2) and ShRUNX2-3 (Sh3) stable melanoma cell lines. D. Levels of RUNX2, FGFR1, 
EGFR, AXL, IGF-1R, PDFGRβ, phosphorylated EGFR (Y1068) and phosphorylated AXL (Y702) in C8161 and C81-61 melanoma cell lines.
Table 1: Proteomics analysis of the ShRNA RUNX2-2- and ShRNA RUNX2-3-expressing 1205LU melanoma cells as 
compared with non-silencing (NS) control 1205LU expressing cells
Receptor tyrosine kinase (RTK) ShRUNX2-2 ShRNA /NS ShRNA ShRUNX2-3 ShRNA /NS ShRNA
IGF-1R NC 0.83
FGFR1 0.71 0.71
PDGFRβ 0.85 0.83
EGFR NC 0.81
The protein expression of the listed receptor tyrosine kinases is expressed as ratio between ShRNA RUNX2-2- or ShRNA 
RUNX2-3-1205LU cells and NS-1205LU cells. PDGFRβ: Platelet-derived growth factor receptor, beta; EGFR: epidermal 
growth factor receptor; FGFR1: fibroblast growth factor receptor 1; IGF-1R: insulin-like growth factor 1 receptor. NC: No 
Change.
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1205LU melanoma cells as compared with the non-
silencing (control) ShRNA-expressing 1205LU cells. 
Because IGF-1R, FGFR1, and EGFR have been shown 
to play major roles in melanoma progression through 
autocrine signaling [32, 34, 36], and EGF-R, PDGFRβ, and 
IGF-1R have been implicated in resistance mechanisms 
to BRAF V600E targeted therapies [19-22, 24, 25], we 
were interested in validating these results. Therefore, 
we compared other melanoma cell lines expressing non-
silencing ShRNA, ShRUNX2-2 or ShRUNX2-3 for the 
expression of these RTKs.
In addition to these RTKs identified by mass 
spectrometry, we were also interested in identifying other 
potential RTKs co-regulated with RUNX2 using patient data. 
Using the CBio Portal for cancer genomics (http://www.
cbioportal.org) [43, 44], we found that the receptor tyrosine 
kinase AXL was co-expressed with RUNX2 (Pearson’s 
correlation = 0.56) after analysis of 278 skin cutaneous 
melanomas (TCGA provisional RNASeqV2 RSEM).
To determine which melanoma cell lines to use 
for validation of the co-expression of RUNX2 and the 
aforementioned RTKs, we analyzed the expression of these 
receptors in a panel of melanoma cell lines. As shown 
in Figure 1A, IGF-1R is expressed by all the melanoma 
cell lines and FGFR1 is highly expressed in 7 out of the 
9 analyzed melanoma cell lines. EGFR is significantly 
expressed in melanoma cell lines with the exception of 
one. AXL is expressed in 6 out of the 9 melanoma cell 
lines tested, and PDGFRβ is expressed at high levels 
in three cell lines and at lower levels or undetectable in 
the others. The expression level of the different RTKs 
seems independent of the stage of progression, when 
we compare cells derived from vertical growth phase 
(VGP) melanomas (WM793, WM278 or WM115) or 
from metastases (WM9, WM16717, 1205LU, C8161 and 
UACC903). We further chose three cell lines (1205LU, 
C8161 and WM35) for which RUNX2 knock down using 
ShRUNX2-2 and ShRUNX2-3 was pronounced to validate 
the co-expression of RUNX2 and RTKs.
Immunoblot analysis of 1205LU cells expressing 
non-silencing ShRNA, ShRUNX2-2 or ShRUNX2-3 
showed reduced levels of IGF-1R and EGFR only in 
ShRUNX2-3-expressing 1205LU cells exhibiting the 
strongest RUNX2 knock down. The expression of 
PDGFRβ showed a decrease in both ShRUNX2-2- and 
ShRUNX2-3-expressing 1205LU cells as compared 
with non-silencing ShRNA-expressing 1205LU control 
cells (Figure 1B, left panel), in accordance with Table 1. 
Therefore, three of the four RTKs that we found negatively 
regulated in the RUNX2-knocked down 1205LU 
melanoma cells by mass spectrometry were validated 
by immunoblot analysis. The expression of IGF-1R 
was reduced in ShRUNX2-3-expressing C8161 cells or 
ShRUNX2-3-expressing WM35 cells, as compared with 
non-silencing ShRNA-expressing C8161 control cells or 
non-silencing ShRNA-expressing WM35 control cells 
respectively. Thus, as described for 1205LU cells, we 
observe a decrease in IGF-1R only in cells demonstrating 
nearly complete RUNX2 knock down (Figure 1B, 
middle and right panels). Like IGF-1R, AXL expression 
is only reduced in ShRUNX2-3-expressing C8161 cells 
as compared with non-silencing ShRNA-expressing 
C8161 cells (Figure 1B, middle panel). EGFR expression 
is diminished in WM35 expressing ShRUNX2-2 or 
ShRUNX2-3 as compared with non-silencing ShRNA-
expressing WM35 cells. The strongest reduction of 
EGFR expression was observed in the ShRUNX2-3-
expressing WM35 cells exhibiting almost complete 
RUNX2 knockdown (Figure 1B right panel). We did 
not detect changes in the expression of FGFR1 in any 
of the RUNX2-knocked down melanoma cell lines (data 
not shown). These results altogether show that RUNX2 
knock down has a negative effect on the expression of 
selected RTKs, with IGF-1R being downregulated in three 
melanoma cell lines exhibiting RUNX2 knock down and 
EGFR in two out of three cell lines.
RTKs stimulation leads to activation of the RAS/
MAPK and PI3K/AKT pathways [45]. Activation of 
the RAS/RAF/MEK cascade leads to ERK1 and ERK2 
phosphorylation [46] at T202/Y204 and T185/Y187 
respectively. After activation of PI3K and subsequent 
conversion of PIP2 to PIP3, AKT binds to PIP3 at the 
membrane allowing PDK1 to phosphorylate T308 leading 
to partial activation of AKT. Phosphorylation of AKT at 
S473 (AKT1) or S474 (AKT2) stimulates full activity 
[47]. We were interested in analyzing whether reduction of 
RTK expression resulted in inhibition of phosphorylation 
of ERK and AKT in RUNX2 knocked down melanoma 
cell lines. Since opposing effects of AKT1 and AKT2 
were described in breast cancer cell migration, AKT1 
suppressing invasion and AKT2 enhancing it [48], we 
analyzed phosphorylation of AKT1 and AKT2, in addition 
to T308 in the RUNX2 knocked down melanoma cell lines. 
As shown in Figure 1C, 1205LU expressing ShRUNX2-3 
demonstrated reduction of AKT phosphorylated at T308 
as compared with the non-silencing controls. In addition, 
in 1205LU melanoma cell lines expressing ShRUNX2-3, 
phosphorylation of AKT2 at S474 was decreased as 
compared with the non-silencing control-expressing 
1205LU cells. No modulation of phosphoAKT1(S473) 
was detected in 1205LU melanoma cells expressing 
ShRUNX2-2 or ShRUNX2-3. By contrast, we did not 
observe any decrease in pAKT(T308), pAKT1(S473) and 
pAKT2(S474) levels in C8161 ShRUNX2-2 or C8161 
ShRUNX2-3 as compared with C8161 expressing the non-
silencing control. This result could be explained by the 
maintained expression of EGFR in C8161 cells expressing 
ShRUNX2-2 or ShRUNX2-3. EGFR expression in those 
lines could trigger phosphorylation/activation of AKT, as 
well as phosphorylation/activation of ERK1/2 as observed 
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in Figure 1C. Furthermore, the reduced expression of 
RUNX2 and RTKs in 1205LU expressing ShRUNX2-3 did 
not result in reduced levels of pERK1/2 levels (Figure 1C). 
1205LU melanoma cells carry the BRAF V600E 
activating mutation responsible to maintain an activated 
MAPK/ERK pathway, reflected in high levels of pERK1/2 
[49]. Therefore, our results are in accordance with earlier 
studies showing that the activation of the MAPK/ERK 
pathway can be driven only by the BRAF activating 
mutation, independently of RTKs activation.
To further analyze the co-expression of RUNX2 and 
RTKs, we examined the expression of RTKs in C81-61 and 
C8161 melanoma cell lines ([50]. The C81-61 cell line is 
derived from a Vertical-Growth Phase Melanoma and the 
C8161 cell line from a metastasis from the same patient. 
As shown in Figure 1D, C81-61 cells had undetectable 
levels of RUNX2, in contrast to C8161 cells. In addition, 
FGFR1, EGFR, and AXL were expressed at high levels in 
C8161 cells as compared to C81-61 cells (Figure 1D). We 
are aware that C8161 and C81-61 cell lines might have 
numerous genetic and epigenetics differences in addition 
to the differential expression of RUNX2. However, it 
indicates that AXL might be an important RTK regulated 
by RUNX2, since we also found decreased levels of 
this RTK in C8161 expressing ShRUNX2-3, which 
induces the strongest RUNX2 knock down. In addition, 
we found high levels of phosphorylated EGFR (Y1068) 
and phosphorylated AXL (Y702) in C8161 melanoma 
cells, in contrast to C81-61 melanoma cells. These results 
suggest that these RTKs are not only up-regulated but also 
activated in C8161 melanoma cells.
RUNX2 and AXL co-expression in melanoma 
samples
The results presented in Figure 1 prompted us to 
analyze the co-expression of RUNX2 and AXL in human 
melanoma samples. First, analysis of 278 cutaneous 
melanomas (TCGA provisional RNASeqV2 RSEM) using 
the CBio Portal for cancer genomics [43, 44] indicated 
that AXL was co-expressed with RUNX2 (Pearson’s 
correlation = 0.56). To confirm the mRNA expression 
results, we performed an immunohistochemical analysis 
of RUNX2 and AXL in the same melanoma tissue 
microarray (TMA). The slides used for RUNX2 and AXL 
immunohistochemical staining were two serial sections 
of the TMA. Figure 2 shows representative pictures of 
RUNX2 and AXL immunostaining of 39 cores expressing 
significant levels of RUNX2 and exhibiting strong diffuse 
(Figure 2A), faint focal (Figure 2B) or no (Figure 2C) 
AXL staining. Analysis of the 39 cores expressing RUNX2 
showed that 7 had strong AXL staining, 23 had faint AXL 
staining and 9 were negative for AXL (Figure 2D). These 
results suggest the co-expression of RUNX2 and AXL 
proteins in a significant number of human melanoma 
lesions.
U1 Adaptor oligonucleotides targeting RUNX2 
inhibit RUNX2 and RTK expression
To confirm the ShRNA data, we used a second and 
novel approach to target RUNX2 expression through a 
new strategy. This strategy uses U1 Adaptors, a recently 
discovered oligonucleotide-based-silencing technology 
whose unique mechanism of action targets nuclear 
pre-mRNA processing. A U1 Adaptor is a synthetic 
oligonucleotide (28-33 nucleotides) containing a 5’ target 
domain, which binds to the target pre-mRNA, and a 3’ U1 
domain that binds to the 5’ end of the U1 small nuclear 
RNA subunit of U1 snRNP. As a result of the tethering 
of the U1 snRNP to the target pre-mRNA, maturation 
is prevented and reduced levels of mature mRNA are 
produced [51]. To deliver the U1 Adaptors to the cells, we 
used a tumor-targeting dendrimer nanoparticle previously 
described [52]. The dendrimer nanoparticle, known 
as RGD-G5, contains the cyclic RGD pentapeptide, 
a tumor targeting ligand, which specifically binds the 
α5β3 splice variant of an integrin cell surface receptor 
overexpressed in a wide variety of cancer cells. The 
RGD targeting ligand was coupled to the generation 5 
(G5) polypropyleneimine (PPI) dendrimer in a final 2:1 
molar ratio to give RGD-G5. Previous studies showed 
that RGD-G5 was active as a delivery vehicle [52]. Using 
the RGD-G5 dendrimer to deliver the U1 Adaptors, 
we screened 6 RUNX2-specific U1 Adaptors for their 
ability to reduce levels of RUNX2 mRNA. For that 
purpose, C8161 and 1205LU cells were incubated in the 
presence of the preformed RGD-G5: RUNX2 U1 Adaptor 
complexes, for 72 hours, and RNA was then extracted. The 
6 RUNX2 U1 Adaptors are designated RA1, RA2, RA3, 
RA4, RA5 and RA6 for RUNX2 Adaptors 1 through 6. 
The control used is designated NC3wt, a U1 Adaptor, 
which does not target any human gene, but can still bind 
U1 snRNP through its U1 domain. As shown in Figure 3A, 
real time PCR determined that RA2 Adaptor was the most 
efficient in reducing RUNX2 mRNA levels in both C8161 
and 1205LU melanoma cells, lowering RUNX2 mRNA 
levels to less than 40% of those in the presence of the 
control NC3wt. For C8161, RA5 and RA6 were efficient 
in reducing to 40 and 60% of the control respectively. For 
1205LU, RA1, RA3 and RA4 decreased RUNX2 levels 
to about 60% of the control. For the next experiments, we 
used RA2 and RA5 Adaptors for C8161 cells and RA2 and 
RA4 Adaptors for 1205LU cells. As shown in Figure 3B, 
RA2 and RA5 for C8161 cells and RA2 and RA4 for 
1205LU cells decreased RUNX2 protein expression.
In order to determine whether decreased RUNX2 
expression translated into reduced RUNX2 activity and 
decreased RTK expression, we analyzed the expression of 
FAK, IGF1R and AXL mRNA by qPCR after transfection 
of C8161 cells with RA2 or RA5 Adaptors and 1205LU 
cells with RA2 or RA4 Adaptors. We previously showed 
that RUNX2 regulates the expression of the FAK protein 
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in melanoma cells [14]. Therefore, we used FAK mRNA 
as a control for RUNX2 loss of activity and confirmed a 
reduction of FAK expression in melanoma cells transfected 
with the selected Adaptors RA2 and RA5 for C8161 
cells, and RA2 and RA4 for 1205LU cells (Figure 3C). 
In addition, these results suggest that the effect of 
RUNX2 on FAK occurs at the transcriptional level. 
We further analyzed the effect of RUNX2 knock down 
on the mRNA expression of two previously identified 
RTKs, IGF-1R and AXL. Figure 3C shows that RA2 and 
RA5 for C8161 and RA2 and RA4 for 1205LU decrease 
AXL mRNA expression, demonstrating that the effect of 
RUNX2 on AXL protein expression (Figure 1B) occurs 
at the transcriptional level. We also found that RA2 
and RA5 decrease IGF-1R mRNA expression in C8161 
melanoma cells (Figure 3C) in contrast to RA2 and RA4, 
which do not inhibit IGF1R mRNA expression in 1205LU 
melanoma cells (data not shown). It is possible that the 
effect of RUNX2 on IGF1R protein expression (Figure 1B) 
does not occur at the transcriptional effect in 1205LU 
melanoma cells. Alternatively, it is also conceivable that 
a complete knock down of RUNX2 has to be achieved 
in order to see an effect on IGF1R mRNA expression in 
1205LU cells as suggested by Figure 1B. Altogether, these 
studies demonstrate that RUNX2-specific U1 Adaptors 
significantly decrease the mRNA and protein expression 
of RUNX2 and mRNA expression of some of its targets 
genes, FAK, AXL and IGF1R.
AKT activity is involved in RUNX2 and RTK 
expression
1205LU cells expressing ShRUNX2-3 and 
exhibiting a decrease in RUNX2, IGF-1R, EGFR 
and PDGFRβ levels also demonstrated a reduction in 
pAKT2 (S474) and pAKT (T308) levels. This suggests 
that RUNX2 might play a role in maintaining activation 
of the PI3K/AKT pathway through the regulation of 
RTKs in some melanoma cells. Furthermore, several 
studies suggested a functional cooperation of RUNX2 
Figure 2: RUNX2 and AXL co-expression in melanoma samples. Representative pictures of strong A., faint B. and negative C. 
AXL staining in RUNX2-expressing melanoma cores from a melanoma tissue microarray. RUNX2 staining (Chromogenic detection using 
red) in on the left panel, corresponding microscopic view of AXL staining (Chromogenic detection using DAB, brown) is on the right 
panel. D. Expression levels of RUNX2 and AXL in the 39 RUNX2-expressing melanoma samples analyzed. The Y axis shows quantitative 
Effective Staining Intensity (ESI; [71]) of RUNX2 in melanoma patient samples. The X axis expresses qualitative analysis of AXL staining 
defined as strong, faint and negative. The scale bar represents 50 μm.
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and the PI3K/AKT pathway as a driving force for tumor 
progression in different cancer types [8]. This functional 
interaction led us to hypothesize that AKT activity 
could also play a role in maintaining RUNX2 levels in 
melanoma cells. To test this hypothesis we used MK2206, 
an allosteric AKT inhibitor [53]. 1205LU and C8161 
melanoma cells were treated with 10 μM MK2206 for 
24 and 48 hours or for 16 and 36 hours respectively. As 
shown in Figures 4A and 4B, treatment with MK2206 
decreased levels of pAKT (S473) as expected for both 
lines while levels of AKT were unchanged. 1205LU 
melanoma cells exhibited reduced levels of RUNX2 
expression at the two time points and a parallel decrease 
in EGFR and AXL expression. C8161 exhibited a decrease 
in RUNX2 expression at the 36-hour time point, with a 
parallel decrease in EGFR and AXL expression. At the 
Figure 3: U1 Adaptor oligonucleotides targeting RUNX2 inhibit RUNX2 and RTK expression. A. Expression of RUNX2 
mRNA 72 hours after transfection of C8161 and 1205LU melanoma cell lines with the complexes, containing the dendrimer nanoparticle 
RGD-G5 and each of the 6 RUNX2 specific U1 Adaptors, named RA1, RA2, RA3, RA4, RA5 and RA6 (RA for RUNX2 Adaptor). This 
experiment, done in triplicate, is representative of three independent experiments. Results are expressed as % of relative RUNX2 mRNA 
normalized to the control NC3wt +/- SEM. B. Immunoblot analysis of RUNX2 expression 72 hours after transfection of C8161 and 
1205LU melanoma cell lines with the complexes, containing the dendrimer nanoparticle RGD-G5 and two selected RUNX2 specific U1 
Adaptors (RA2 and RA5 for C8161, RA2 and RA4 for 1205LU). C. Expression of FAK, IGF-1R and AXL 72 hours after transfection of 
C8161 cells with the RGD-G5-RA2 and RGD-G5-RA5 complexes and 72 hours after transfection of 1205LU cells with the RGD-G5-
RA2 and RGD-G5-RA4 complexes. The samples were analyzed in quadruplicate. This experiment is representative of three independent 
experiments. Results are expressed as % of relative FAK, IGF1R or AXL mRNA normalized to the control NC3wt +/- SEM. * indicates p 
< 0.05, ** indicate p < 0.01 and *** indicate p < 0.001 compared with NC3wt based on Student’s t-test.
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16-hour time point, C8161 cells showed a decrease in 
AXL expression while RUNX2 levels were unchanged. 
This data suggests that MK2206 effect on AXL expression 
could be RUNX2 dependent or RUNX2 independent.
RUNX2 isoforms 1, 2 and 3 are expressed at 
varying levels in melanoma cells
We previously published the expression of RUNX2 
in melanoma cell lines and RUNX2 appeared as a single 
band on low exposure [14]. However, three main RUNX2 
isoforms are produced through alternative splicing. 
Isoform 1 (identifier Q13950-1) is the chosen canonical 
sequence and the longest isoform. Isoform 2 (identifier 
Q13950-2) has a different N terminal domain as compared 
with isoform 1: 1-19: MASNSLFSTVTPCQQNFFW → 
MRIPV. Isoform 2 is shorter than isoform 1. Isoform 3 
(identifier Q13950-3) differs from isoform 1 by an internal 
deletion for which amino acids 341-362 are missing. To 
analyze the presence and expression of RUNX2 isoforms 
in human tumors, we downloaded isoform expression 
data from 471 samples from the TCGA-SKCM cohort. 
Figure 5A shows the distribution of normalized expression 
values of the three isoforms in this set (histogram, log-
transformed expression values on the x-axis). Isoforms 2 
and 3 are expressed in the cohort, while isoform 1 is mostly 
not present. Isoforms 2 and 3 are expressed together with 
a correlation of 0.79 (p<1.0e-100). Using a monoclonal 
antibody raised against a synthetic peptide surrounding 
A273 of human RUNX2 we were able to detect the three 
isoforms, as shown in Figure 5B. In accordance with 
the TCGA data analysis, isoform 1 is expressed at lower 
level than isoforms 2 and 3, which often appear together 
as a thicker band (Figure 5B). Experiments presented on 
Figures 1, 3 and 4 mainly showed isoforms 2 and/or 3 
because of the low expression of isoform 1 as compared 
with the other two isoforms. The experiments presented in 
Figure 5C (see below) show the appearance of isoform 1 
at higher levels.
Increased expression of RUNX2 isoforms in 
melanoma cells resistant to BRAF V600E 
inhibition
The up-regulation of EGF-R, PDGFRβ, AXL 
and IGF-1R expression/activity plays a crucial role in 
resistance mechanisms to targeted therapies using BRAF 
V600E inhibitors [19-22, 24, 25]. Since we showed co-
regulation of RUNX2 and those RTKs, we postulated 
that resistance to BRAF V600E inhibition could be 
associated with an increase in RUNX2 expression. In 
the first set of experiments, 1205LU melanoma cells 
were treated with the BRAF V600E inhibitor PLX4720 
in vitro and clones resistant to PLX4720 were selected 
and expanded. Two clones resistant to 0.5 μM, three 
clones to 3 μM and one clone to 5 μM PLX4720 were 
analyzed for RUNX2 expression. As shown in Figure 
5C (low exposure), two out of three clones resistant to 
3 μM PLX4720 (clones 1 and 3), exhibited increased 
level of RUNX2 isoforms 2/3, while an increase in 
Figure 4: AKT activity is involved in RUNX2 and RTK expression. 1205LU A. and C8161 B. melanoma cell lines were treated 
with vehicle (DMSO, (D)) or 10 μM MK2206 (MK) for the indicated times. Lysates were analyzed for the expression of pAKT, AKT, 
RUNX2, EGFR, AXL and Actin.
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isoform 1 was observed in all but one clone resistant to 
PLX4720. All the clones expressing RUNX2 isoform 1 
showed increased levels of EGFR and IGF-1R, while 
we found increased AXL expression in clones 1 and 
3 up-regulating RUNX2 isoforms 2/3 in addition to 
isoform 1. We further analyzed four of the six 1205LU 
clones resistant to PLX4720 (clones 1,4, 5 and 6) for 
the levels of phosphorylated/activated EGFR and IGF-
1R. We demonstrate increased expression of pEGFR 
(Y1068) and pIGF-1R (Y1135/1136) in the four clones 
as compared with the parental 1205LU melanoma cells 
(Figure 5D). In addition, we show constitutive ERK1/2 
and AKT (S473 and T308) phosphorylation in those 
four PLX4720 resistant clones (Figure 5E). Therefore, 
our results show an increase in RUNX2 levels and an 
associated increase in RTK levels and activation in 
1205LU clones resistant to PLX4720.
In the second set of experiments we took advantage 
of the existence of cell lines established from PLX4720-
resistant tumors (PRT) in Dr. A. Aplin’s laboratory 
(Kimmel Cancer Center Philadelphia, PA) [54, 55]. 
Briefly, 1205LU xenograft tumors initially shrank in 
the presence of PLX4720 and rapid regrowth occurred 
associated with ERK1/2 reactivation [54, 55]. Five cell 
lines established from the resistant tumors, PRT3, PRT4, 
PRT6, PRT9 and PRT11 were treated with vehicle or 1 
μM PLX4720 for 24 hours in vitro as previously described 
[54]. As shown in Figure 6A, the expression of RUNX2 
isoforms 2/3 was increased in the five PRT lines in the 
presence of PLX4720. An increase of isoform 1 was 
only observed in PLX4720-treated PRT3. These results 
suggest that PLX4720-resistant cells developed in an 
in vivo context can exhibit an increase in RUNX2 levels 
when reexposed to PLX4720 in vitro. These findings 
Figure 5: Increased expression of RUNX2 isoforms and RTKs in melanoma cells resistant to BRAF V600E inhibition. 
A. An isoform level analysis of RUNX2 expression in 471 samples from the TCGA-SKCM (Skin Cutaneous Melanoma) cohort shows 
expression of variants 2 and 3 in the cohort, while variant 1 is mostly absent. Shown is the distribution of log-transformed expression values 
for each isoform (X axis) across the samples. Y axis: Number of samples. B. Expression of RUNX2 isoforms 1, 2 and 3 in melanoma cell 
lines. C. Clones resistant to 3 μM (clones 1-3), 5μM ((clone 4) and 0.5 μM (clones 5 and 6) PLX4720 were analyzed for RUNX2, EGFR, 
IGF-1R and AXL expression. P: Parental 1205LU melanoma cell line. D. Levels of pEGFR (Y1068) and pIGF-1R (Y1135/1136) in parental 
1205LU melanoma cells (P) and clones 1, 4, 5 and 6 resistant to PLX4720. E. Levels of pERK1/2, pAKT (pan) (S473), pAKT (T308), 
ERK1/2 and AKT in clones 1, 4, 5 and 6 resistant to PLX4720.
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Figure 6: A. Expression of RUNX2 and RTKs in melanoma cells rendered resistant to BRAF V600E inhibition in vivo. 
Melanoma cell lines established from PLX4720-resistant 1205LU xenografts (PRT lines 3, 4, 6, 9 and 11) were incubated in the presence of 
DMSO (D) or 1 μM PLX4720 (PLX) for 24 hours and RUNX2, AXL, IGF-1R and EGFR expression was analyzed. Low and high exposures 
for IGF1R are shown. B. Patient data from a cohort containing samples from untreated tumors and tumors treated with Vemurafenib and 
Dabrafenib respectively [56] were downloaded from GSE50509. Expression of RUNX2 transcripts 1, 2 and 3 in untreated and Vemurafenib 
and Dabrafenib treated groups. P-values were calculated using a t-test between untreated and vemurafenib treated groups.” C. 1205LU 
melanoma cells expressing non-silencing ShRNA (NS), ShRUNX2-2 (Sh2) or ShRUNX2-3 (Sh3) were treated with Vehicle (DMSO) or 10 
μM PLX 4720 for 72 hours and viable cells were then counted. This experiment, done in triplicate, is representative of three independent 
experiments. Results are expressed as % (cell numbers in the presence of PLX4720 / cell numbers in the presence of DMSO). *** indicate 
p < 0.001 compared with NS.
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would also suggest that RUNX2 might be involved in 
acquired resistance. In parallel to the RUNX2 increase, 
we observed an increase in IGF-1R expression in four 
out of five PLX4720-treated PRT lines (PRT lines 3, 
4, 9 and 11) and in AXL expression in three out of five 
PLX4720-treated PRT lines (PRT lines 4, 9 and 11). High 
endogenous EGFR expression in those PRT lines was not 
further modulated in the presence of PLX4720.
To address the relevance of these findings in human 
melanoma, patient data from a cohort containing samples 
from untreated tumors and tumors treated with vemurafenib 
and dabrafenib respectively [56] were downloaded from 
GSE50509. The data was analyzed on probe level in order 
to avoid low expressed variants to distort the evaluation. 
Probes for all three transcript variants were represented on 
the Illumina array. The expression of RUNX2 isoform 3 
was significantly higher in vemurafenib treated patients 
compared to the untreated group (p=0.0024, Student’s 
T-test). The expression of isoform 2 was slightly increased 
in this group (p=0.0882), while isoform 1 was not 
significantly changed among the groups (Figure 6B). These 
results showing the up-regulation of specific isoforms of 
RUNX2 in melanoma lesions from patients treated with 
Vemurafenib, suggest that chronic exposure to BRAF 
V600E inhibitors (PLX4720/Vemurafenib) may favor 
RUNX2 up-regulation and subsequent RTK up-regulation, 
an important player in acquired resistance to these drugs.
To determine whether RUNX2 expression played 
a role in sensitivity to PLX4720, we treated 1205LU 
melanoma cells expressing non-silencing ShRNA, 
ShRUNX2-2 or ShRUNX2-3 with 10 μM PLX4720 for 
72 hours and counted viable cells. As shown in Figure 6C, 
RUNX2 knock down resulted in an increased sensitivity 
to PLX4720 as compared with control cells.
DISCUSSION
In late stage melanomas, receptor tyrosine kinase-
based autocrine loops contribute to the activation of 
pathways such as MAPK and PI3K/AKT [57]. However, 
little is known about the molecular events involved in 
the dysregulation of RTKs expression/activity. Our data 
identifies a candidate for this dysregulation. We initially 
demonstrated the over-expression of transcriptionally 
active RUNX2 in melanoma cell lines and melanoma 
samples as compared with primary melanocytes and 
melanocytic nevi respectively. We also implicated RUNX2 
as an important factor in melanoma migration and invasion 
[14]. Our present study points to RUNX2 as a potential 
regulator of AXL, EGFR, IGF-1R and PDGFRβ and to 
a lesser extent FGFR1 expression. This conclusion is 
based on: 1) the down regulation of AXL, EGFR, IGF-1R 
and PDGFRβ in ShRUNX2 knocked down melanoma 
cell lines or RUNX2-specific U1 Adaptors-transfected 
melanoma cells. 2) The higher expression of FGFR1, 
EGFR and AXL in C8161 cells as compared with C81-61 
cells, which parallels the higher level of expression of 
RUNX2 in C8161 cells; 3) the co-regulation of RUNX2 
and AXL in a significant number of human melanoma 
samples (7 out of 39 samples with positive RUNX2 
staining had strong AXL staining); 4) The increase in 
EGFR, IGF-1R and AXL expression in 1205LU clones 
resistant to the BRAF V600E inhibitor PLX4720 in 
association with dramatic RUNX2 up-regulation in 5 out 
of 6 clones analyzed; 5) The increase in IGF-1R and AXL 
expression in association with RUNX2 up-regulation in 
three out of five PLX4720-Resistant Tumor (PRT)-derived 
cell lines treated in vitro with PLX4720 as compared 
with vehicle-treated PRT cells. Furthermore, our results 
strongly suggest that RUNX2 might be a mediator of 
resistance to BRAF V600E targeted therapy, involving 
RTK up-regulation and activation in melanoma. A working 
model based on our findings is presented in Figure 7.
Because RUNX2 expression and activity are 
positively regulated by the PI3K and MAPK pathways [8], 
it is necessary to explore the relationship between IGF-
1/IGF-1R and RUNX2. IGF-1 was shown to positively 
regulate RUNX2 expression in endothelial cells (EC) [13] 
and osteoblasts [58], and to stimulate RUNX2 activity 
in EC [59] and osteoblasts [60]. In EC, IGF-1 regulates 
RUNX2 DNA binding through sequential activation of 
the PI3K/Pak1 and ERK1/2 signaling cascade [59], but 
independently of AKT. Another mechanism of IGF-1-
mediated increase in RUNX2 activity has been proposed 
in osteoblasts. The transcription factor FOXO1 physically 
interacts with RUNX2 in osteoblastic cells and in COS-7 
cells and inhibits RUNX2 binding to its cognate site within 
the osteocalcin promoter. Upon IGF1/insulin binding to 
their receptors, activation of the PI3K/AKT pathway leads 
to phosphorylation and nuclear exclusion of FOXO1 and 
reactivation of RUNX2 [60]. We speculate that similar 
regulation of IGF-1 on RUNX2 expression and activity 
could exist in melanoma cells, through the activation of 
IGF-1R and subsequent stimulation of the PI3K and/or the 
MAPK pathways resulting in RUNX2 positive regulation. If 
such a system exists, the regulation of IGF-1R by RUNX2 
shown in the present study would suggest the existence 
of a positive feedback loop of RUNX2/IGF-1/IGF-1R 
in melanoma cells, promoting melanoma migration and 
invasion. Similarly, the positive regulation of AXL, EGFR 
and PDGFRβ by RUNX2 could result in an activation of 
these receptors in the presence of their ligands (provided by 
melanoma cells or the melanoma cell microenvironment) 
thereby promoting stimulation of the PI3K and MAPK 
pathway and RUNX2 positive regulation (as shown in 
Figure 7).
AXL belongs to the TAM (Tyro3, AXL, MER) 
family of RTKs [61]. Real time PCR examination of 8 
AXL-positive tumors demonstrated that MER and TYRO3 
transcripts were barely detectable and immunoblot 
analysis of representative melanoma cell lines confirmed 
mutual exclusion of AXL and TYRO3 and frequent 
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co-expression of TYRO3 and MER [40]. Another study 
analyzed active RTKs in melanoma cell lines through 
measurement of their level of tyrosine phosphorylation 
and found that AXL, TYRO3 and MER were among 
the RTKs with the highest overall activation level. Co-
activation of TYRO3 and MER was also frequently 
observed in these melanoma cell lines [35]. TYRO3 
has been identified as an upstream regulator of the 
Microphthalmia-associated transcription factor (MITF). 
TYRO3 induces MITF-M expression in a SOX10-
dependent manner in melanoma cells [62], while other 
studies showed the anti-correlation between MITF and 
AXL in melanoma cells [40, 41]. These results suggest 
that AXL and TYRO3 might play different roles in 
melanoma progression, perhaps in relationship with MITF 
expression. Interestingly, eighteen AML1a (RUNX1) 
binding sites have been predicted to exist in the TYRO3 
promoter, according to DECODE (DECipherment Of 
DNA Elements), a SABiosciences’ proprietary database 
combining their Text Mining Application and data from 
the UCSC Genome Browser. Therefore, a parallel can be 
drawn between the regulation of AXL by RUNX2 and 
the potential regulation of TYRO3 by RUNX1. However, 
more studies are required to confirm the regulation of 
TYRO3 by RUNX1, and to decipher the role of RUNX1 
in melanoma cells, which is co-regulated with RUNX2 
with a Pearson’s Correlation of 0.31 in cutaneous 
melanoma (TCGA provisional, 278 samples) using CBio 
Portal (http://www.cbioportal.org) [43, 44].
We show that when the five PRT lines derived from 
the PLX4720-resistant 1205LU melanoma xenografts are 
treated in vitro with PLX4720, all PRT lines exhibit an 
increased RUNX2 expression (isoforms 2/3) as compared 
with vehicle-treated cells. In addition, we demonstrate 
an increase in IGF-1R expression in four out of the five 
PLX4720-treated PRT lines, while AXL expression is 
increased in three out of five PLX4720-treated PRT lines. 
PRT lines 4, 9 and 11 show parallel increase in RUNX2, 
IGF-1R and AXL (Figure 6A). The selective increase in 
RUNX2 isoforms 2/3 observed in PLX4720-treated PRT 
lines derived from PLX4720-resistant tumors (Figure 6A) 
and in Vemurafenib-treated patients (Figure 6B) is in 
apparent contradiction with the high expression of isoform 
1 in all but one 1205LU clones developing resistance to 
PLX4720 in vitro (Figure 5C). In 1205LU clones developing 
resistance in vitro, two of the six clones expressed increased 
levels of isoforms 2/3. The tumor microenvironment present 
during the in vivo treatment with the BRAF V600E inhibitors 
(PLX4720-treated xenografts and Vemurafenib-treated 
patient tumors) but absent in clones developing PLX4720 
resistance in vitro, likely plays a role in these differences in 
the type of RUNX2 isoforms up-regulated.
Interestingly, PRT6 was shown to carry a HRAS 
Q61K mutation; PRT3 was shown to express a previously 
Figure 7: Working model for the role of RUNX2 in RTK-based autocrine loops and resistance to BRAF V600E targeted 
therapy. RUNX2 regulates RTK expression by mechanisms yet to be defined. Treatment of melanoma cells with BRAF V600E inhibitors 
(PLX4720, Vemurafenib) eventually results in up-regulation of RUNX2 and subsequent up-regulation of RTKs, implicated in resistance 
to BRAF V600E targeted therapy, through increased proliferation, survival, migration and invasion. Reactivation of the oncogenic MAPK 
pathway through RTK up-regulation compensates for the inhibition of BRAF V600E. Those RTKs also signal through the PI3K/AKT 
pathway and AKT activation contributes to maintain high RUNX2 levels. This positive feedback loop contributes to drive progression of 
resistant melanoma cells.
Oncotarget29701www.impactjournals.com/oncotarget
unreported variant that splices exon 2 with exon 11 of BRAF 
V600E; PRT4 was found to express a variant previously 
reported from a patient sample that splices exon 1 with 
exon 9 of BRAF V600E. Both PRT3 and PRT4 maintained 
V600E positivity [54]. The BRAF V600E variants and the 
HRAS mutation were sufficient for resistance to PLX4720 
treatment. This study illustrates that from a single cell line, 
multiple mechanisms of resistance could emerge [54]. 
Due to the heterogeneity of resistant tumors, these authors 
proposed taking several biopsies from multiple sites for 
molecular analysis [54]. Our data suggests that in addition 
to examining RAS mutations and BRAF variants during 
the molecular analysis of tumor samples, we should also 
include the analysis of RTK up-regulation/activation, as it 
participates in a significant number of acquired resistance 
mechanisms, possibly in conjunction with RAS mutation 
or the existence of V600E splicing variants.
Regarding resistance to RTK inhibition, we observed 
that downregulation of IGF-1R and AXL in C8161 
melanoma cells expressing ShRUNX2-3 (Figure 1B) 
did not result in reduced AKT and ERK phosphorylation 
(Figure 1C) but instead increased AKT phosphorylation. 
It is possible that the increased activation of EGFR whose 
expression was unchanged or expression/activation 
of another RTK compensated for the reduction in IGF-
1R- and AXL-mediated signaling. Such a compensatory 
mechanism has been described in non-small cell lung 
cancer (NSCLC) cells: Treatment with the EGFR erlotinib 
inhibitor induced heterodimerization of insulin-like 
growth factor receptor/epidermal growth factor receptor, 
activated IGF-1R and downstream signaling mediators, 
which ultimately counteracted the antitumor action of 
erlotinib in NSCLC cells [63]. These results support the 
hypothesis that the reactivation of other RTKs (through 
homo or heterodimerization) is likely to happen following 
down regulation of one or two RTKs or their inhibition by 
small molecules inhibitors.
We demonstrated that RUNX2 knock down 
resulted in down regulation of FAK ([14] and Figure 3) in 
addition to IGF-1R, EGFR, PDGFRβ and AXL decrease. 
Interestingly, disruption of the protein interaction 
between FAK and IGF-1R by a small molecule (INT2-
31) induced apoptosis and cell cycle arrest, inhibited AKT 
phosphorylation in vitro and in tumors, and decreased 
growth of melanoma xenografts [37]. These results 
suggest that targeting RUNX2 expression or activity might 
induce similar effects by negatively affecting FAK-IGF-
1R interaction. In addition, the involvement of RUNX2 
in the regulation of four different RTKs implicated in 
melanoma progression and acquired resistance to BRAF 
V600E inhibitors suggests that RUNX2 is a potential 
therapeutic target in patients with melanoma. RUNX2 
belongs to a class of proteins traditionally considered 
undruggable. However, transcription factors have 
become the focus of new targeting strategies: These new 
strategies exploit the fact that transcription factor activity 
is regulated at distinct levels and that we can interfere 
with each of these levels, including specific binding to 
cis-regulatory elements or homo- and hetero-dimerization 
[64, 65]. There is increasing evidence that transcription 
factors play oncogenic roles in melanoma and this has 
driven efforts to develop new approaches to target this 
class of proteins [66]. Targeting RUNX2 binding to cis-
regulatory elements and RUNX2 interaction with major 
co-activators/transcription partners, such as SMADS [8, 
67] are likely to open new avenues of therapy for patients 
with melanoma.
MATERIALS AND METHODS
Cell lines
WM9, WM1617, WM793, WM278, and 1205LU 
were kindly provided by Dr. M. Herlyn (Wistar Institute, 
Philadelphia, PA, USA [49]). These lines were cultured in 
MCDB153/L-15 (4/1 ratio) medium containing 2% FBS, 
5 μg/ml Insulin and 1.7 mM Calcium Chloride. C8161 and 
C81-61 melanoma cell lines were provided by Dr. Mary 
Hendrix (Children’s Memorial Research Center, Chicago, 
IL, USA [50] and were grown in D-MEM (Mediatech, 
10-013-CV) containing 10% FBS. UACC903 and 
UACC930 cells were provided by Dr. Jeffrey M. Trent 
(Translational Genomics Research Center, Phoenix, AZ, 
USA [68]) and were grown in RPMI1640 (Invitrogen, 
11875) containing 10% FBS. WM115 and WM35 
melanoma cell lines were purchased from ATCC 
(American Type Culture Collection, Manassas, VA 
20110, U.S.A). WM35 and WM115 [49] were grown in 
MCDB153/L-15 (4/1 ratio) medium containing 2% FBS, 
5 μg/ml Insulin and 1.7 mM Calcium Chloride. PLX4720 
resistant clones were kindly provided by Dr S. Chen 
(Rutgers University, Piscataway NJ). Briefly, 2-4 x 105 
1205LU melanoma cells were plated in a 60 mm dish in 
the presence of increasing concentrations of PLX4720 
(from 0.1 to 5 μM). Resistant clones were then expanded 
successively in 24-well plates, 35 and 60 mm dishes in 
the presence of the respective concentrations of PLX4720.
Treatment with pharmacological agents
For MK2206 treatment, 1205LU and C8161 
melanoma cell lines were treated with vehicle (DMSO) 
or the allosteric AKT inhibitor, MK2206 (10 μM), for 
24 and 48 hours and for 16 and 36 hours respectively. 
Whole cell lysates were then prepared as described below 
in the immunoblotting section. For PLX4720 treatment 
of 1205LU melanoma cells expressing non-silencing 
ShRNA, shRUNX2-2, or ShRUNX2-3, 105 cells were 
seeded, treated the next day with 10 μM PLX4720 for 
72 hours and then counted using a Vi-Cell counter. 
For PLX4720 treatment of the PRT lines, 5x105 PRT 
(PLX4720-Resistant Tumors) -derived cell lines (PRT 
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lines 3, 4, 6, 9 and 11 [54]) were seeded on a 10 cm plate 
and allowed to proliferate without drug for 72 hrs. Then 
cells were then treated with vehicle (DMSO) or 1 μM 
PLX4720 for 24 hrs, before protein extraction.
Proteomics analysis of ShRNA RUNX2-
expressing melanoma cells using iTRAQ protocol
Samples were lysed as previously described [14]. 
The protein samples (120 ug) were run into a Novex Bis-
Tris 10% gel as gel plugs and digested with trypsin using 
standard protocol. The digested peptides were washed 
with methanol and labeled with iTRAQ reagent (Sciex) 
using manufacturer’s recommended protocol and then 
combined.
High-pH Reverse phase HPLCs were used for 
peptide fractionation using Gilson 300 series. Samples 
were solubilized in 200 μl of 20 mM ammonium formate 
(pH10), and injected onto an Xbridge column (Waters, 
C18 3.5 μm 2.1X150 mm) using a linear gradient of 
1%B/min from 2-45% of B (buffer A: 20 mM ammonium 
formate, pH 10, B: 20 mM ammonium formate in 90% 
acetonitrile, pH10). 1min fractions were collected and 
speed vac dried.
Selected fractions were either combined or directly 
analyzed by LC-MS/MS. 5μl /12.5 μl of fractionated 
samples were analyzed by nanoLC-MS/MS using a RSLC 
system (Dionex, Sunnyvale CA) interfaced with a LTQ 
Orbitrap Velos (ThermoFisher, San Jose, CA). Samples 
were loaded onto a self-packed 100μm x 2cm trap packed 
with Magic C18AQ, 5μm 200 A (Michrom Bioresources 
Inc, Aubum, CA) and washed with Buffer A (0.2% formic 
acid) for 5 min with a flow rate of 10ul/min. The trap was 
brought in-line with the homemade analytical column 
(Magic C18AQ, 3μm 200 A, 75 μm x 50cm) and peptides 
fractionated at 300 nL/min with a multi-stepped gradient 
(4 to 15% Buffer B (0.16% formic acid 80% acetonitrile) 
in 25 min and 15-25%B in 65 min and 25-50%B in 55 
min). Mass spectrometry data was acquired using a data-
dependent acquisition procedure with a cyclic series of a 
full scan acquired in Orbitrap with resolution of 60,000 
followed by MSMS scans (HCD 38% of collision energy) 
of 10 most intense ions with a repeat count of two and the 
dynamic exclusion duration of 60 sec.
The LC-MSMS data was searched against the human 
Ensembl database using an in house version of X!tendem 
(SLEDGEHAMMER (2013.09.01),thegpm.org) with 
carbamidomethylation on cysteine and iTRAQ labeling on 
lysine and N-terminus of the peptide as fixed modification 
and oxidation of methionine as variable modification using 
a 10 ppm precursor ion tolerance and a 20 ppm fragment 
ion tolerance. Intensity of iTRAQ reporter ions of each 
spectrum was extracted using an in-house perl script 
corrected for isotope cross-over using values supplied by 
the manufacturer. The ratio was normalized using median 
intensity ratio of all identified spectra that fit certain 
criteria: peptide log€ <-1.5, sum of reporter ion intensity 
>4,000. Protein ratios were calculated using median value 
of ratios of all peptides belonging to the same protein that 
fits criteria described above.
Immunoblotting
Cells were harvested, washed with PBS, and 
lysed with cell lysis buffer in the presence of protease 
and phosphatase inhibitors (Roche) as previously 
described [14]. Equal amounts of protein were separated 
on polyacrylamide gel electrophoresis and transferred 
onto nitrocellulose membrane, and immunoblots were 
analyzed using antibodies against RUNX2, GAPDH, 
FAK, EGFR, PDGFRβ, FGFR1, IGF-1R, pAKT1 (S473), 
pAKT2 (S474), pAKT (T308), phosphop44/42 MAPK 
(ERK1/2) (T202/Y204), pEGFR (Y1068), pAXL (Y702) 
from Cell Signaling (Danvers, MA), AXL from R&D 
systems (Minneapolis, MN), pIGF-1R (Y1135/1136) from 
ThermoFisher Scientific (Rockford, IL) and Actin (Sigma 
Aldrich, St. Louis, MO).
Detection of AXL by immunohistochemistry
The human melanoma tissue microarray (TMA 
number ME1004A) was purchased from US Biomax, 
Inc. (Rockville, MD, USA). The melanoma TMA was 
deparaffinized and antigen retrieval was performed using 
extended CC1 treatment (Cell Conditioning Solution, 
Ventana Medical Systems, Oro Valley, AZ). The goat 
polyclonal antibody for AXL (R&D) was applied 
and incubated at 37°C for 1 or 2 hours. Donkey anti-
goat secondary antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA) was then applied and 
incubated at 37°C for 60 min, followed by chromogenic 
detection using the DAB Map kit (Ventana Medical 
Systems, Oro Valley, AZ). Slides were counterstained 
with Hematoxylin and dehydrated and cleared before 
coverslipping from Xylene. RUNX2 staining was done as 
previously described [14].
Analysis of IHC staining
Tissue microarray specimens were imaged using 
Trestle® whole slide imaging system under a 20x 
objective. Custom whole slide visualization software 
[69] developed at Center for Biomedical Imaging & 
Informatics, Rutgers Cancer Institute of Pathology, was 
used to display high-resolution, synchronized, side-by-
side views of corresponding TMA cores stained with 
RUNX2 and AXL and a board-certified pathologist 
examined tissue composition and staining intensity 
at each TMA core location. Quantification of RUNX2 
expression was previously reported [14]. Due to the 
presence of non-melanoma cells staining and melanin 
in the specimen, evaluation of AXL expression level 
was conducted in a semi-quantitative manner. A board-
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certified pathologist closely examined side-by-side 
views of each AXL stained TMA core with its RUNX2 
staining counterpart, and determined co-localizing AXL 
expression level in melanoma cells to be “Strong”, 
“Faint” or “Negative”.
RUNX2 knock down using ShRNA
We used two different human RUNX2 ShRNA, 
targeting either the coding sequence (ShRUNX2-3) or 
the 3’UTR (ShRUNX2-2), in the pGIPZ lentiviral vector. 
The mature senses were CCAGCTGCATCCTATTTAA 
for ShRUNX2-2 and ACAAGGACAGAGTCAGATT 
for ShRUNX2-3. The mature sense was 
ATCTCGCTTGGGCGAGAGTAAG for the non-silencing 
control. This sequence does not match any known 
mammalian gene (has at least 3 or more mismatches 
against any gene as determined via nucleotide alignment/
BLAST of 22mer sense sequence). 80-90 % confluent 
293 amphotropic cells were transfected with 10 μg of 
non-silencing control or shRUNX2 plasmid and 4 μg of 
PREV (pcmv-dR8.2 dvpr) plasmid using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). 48 hours following 
transfection, the supernatant media was filtered through 
a 0.4uM filter for infection. Melanoma cell lines C8161, 
WM35 and 1205LU were seeded at a density of 0.2 x 106 
cells/ 6 well plate 24 hours prior to the infection. The cells 
were then infected with 1 ml viral particles and 8ug/ml 
polybrene and after 6 hours, 1ml fresh media was added 
and incubated for overnight. The following day, cells 
were incubated with 2 ml fresh media followed by stable 
selection with 3 μg/ml Puromycin for 1 to 2 weeks.
RUNX2 mRNA targeting using anti-RUNX2 U1 
Adaptors
The panel of anti-RUNX2 U1 Adaptors was 
designed by and then purchased from Silagene Inc. 
(Hillsborough, NJ). The RGD-G5 dendrimer was prepared 
as previously described [52]. The 1205LU and C8161 cells 
were plated at 200,000 cells per well in a 6 well plate. 
Transfection of anti-RUNX2 U1 Adaptors or control U1 
Adaptors in complex with RGD-G5 dendrimers was done 
as follows: for a 6-well plate, a 0.2 ml transfection mix 
containing 20mM HEPES buffer pH 7.4 in water was 
prepared containing 200nM U1 Adaptor and 1500nM 
RGD-G5 dendrimer, and the solution gently mixed. The 
RGD-G5:anti-RUNX2 U1 Adaptors complexes were 
then added to cells that had been overlaid with 1.8 ml of 
fresh growth media giving a final concentration of 20nM 
U1 Adaptor and 150nM RGD-G5 dendrimer. After 72 
h, either total RNA was extracted for qPCR or protein 
extracted for Western blotting.
RNA extraction, RT-PCR and real-time PCR for 
the experiments with U1 Adaptors
Total RNA was extracted from transfected cells 
using Trizol reagent (Invitrogen,Carlsbad, CA) and further 
purified using NucleoSpin RNA kit (Macherey-Nagel, 
Germany) according to the manufacturer’s instructions. 
500 ng of total RNA was used for cDNA synthesis with 
random hexamers using high capacity cDNA reverse 
transcription kit (Applied Biosystems) according to the 
manufacturer’s instructions. For RT-PCR amplifications 
SYBR Green PCR master mix (Applied Biosystems) was 
prepared with appropriate forward and reverse primers 
and cDNA according to the manufacturer’s instructions. 
The thermal cycling conditions were composed of an 
initial denaturation step at 95°C for 10 min, 40 cycles 
at 95°C for 30s, 55°C for 30s and 72°C for 30s with a 
Mx3000P (stratagene). A melting curve was generated by 
slowly increasing (0.1°C/s) the temperature from 60°C to 
95°C, while the fluorescence was measured. Reactions 
were run in duplicates in three independent experiments. 
The housekeeping gene GAPDH was used as an internal 
control for normalization. The fold change in the mRNA 
levels in the RUNX2 U1 Adaptor-transfected cells was 
analyzed by comparing to RGD-G5 transfected cells 
using the 2 -ΔΔCT method previously described [70]. The 
results are presented as percentage of RUNX2 remaining 
by setting the value from RGD-G5 transfected cells to 
100%. Data from qPCR experiments are presented as the 
average ± standard error of the mean. Statistical analysis 
was performed by Student’s t test and P values < 0.05 
were considered statistically significant.
Patient data analysis
Level 3 RNASeqV2 isoform expression data 
from 471 samples in the TCGA-SKCM cohort were 
downloaded and RUNX2 isoform probes corresponding 
to the three variants were selected. The rsem normalized 
values were log-transformed (log2(data+1)) and a 
histogram was generated using the MATLAB routine hist.
Patient data from a cohort containing samples from 
untreated tumors and tumors treated with vemurafenib 
and dabrafenib respectively [56] were downloaded from 
GSE50509. The data was downloaded in the pre-normalized 
form, and probes for RUNX2 were selected. We used the 
box plot routine (MATLAB) to plot the three different 
treatment groups for all probes individually. The plot shows 
data between 25th and 75th percentile within the blue boxes 
and the median as red line in each group. Whiskers indicate 
the 5th and 95th percentiles and outliers are indicated as 
data points in red. P-values were calculated using a t-test 
between untreated and vemurafenib treated groups.”
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